Search Results

You are looking at 1 - 10 of 862 items for :

  • "NCCN Clinical Practice Guidelines in Oncology NCCN Guidelines" x
  • Refine by Access: All x
Clear All
Full access

Robert A. Swarm

remains less than 0.01 to 0.1 mg per person per year. Current NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) “go much further” than the WHO Analgesic Ladder, he noted. The NCCN Guidelines mandate universal screening for pain in all

Full access

Presenter: Shaji K. Kumar

have to come up with new treatment approaches to maintain control over a long period of time.” Monoclonal Gammopathies of Clinical Significance The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Multiple Myeloma outline the

Full access

Potjana Jitawatanarat, Arpita Desai, Pradeep Sharda, Hong Liu, Maureen Ross, Francisco J. Hernandez-llizaliturri, Philip L. McCarthy, and George L. Chen

confers the worst prognosis. Favorable risk factors include del(13q) and a lymphocyte doubling time that is greater than a year. The CLL section of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non–Hodgkin’s Lymphoma recommends

Full access

David S. Ettinger, Douglas E. Wood, Dara L. Aisner, Wallace Akerley, Jessica R. Bauman, Ankit Bharat, Debora S. Bruno, Joe Y. Chang, Lucian R. Chirieac, Thomas A. D’Amico, Thomas J. Dilling, Jonathan Dowell, Scott Gettinger, Matthew A. Gubens, Aparna Hegde, Mark Hennon, Rudy P. Lackner, Michael Lanuti, Ticiana A. Leal, Jules Lin, Billy W. Loo Jr, Christine M. Lovly, Renato G. Martins, Erminia Massarelli, Daniel Morgensztern, Thomas Ng, Gregory A. Otterson, Sandip P. Patel, Gregory J. Riely, Steven E. Schild, Theresa A. Shapiro, Aditi P. Singh, James Stevenson, Alda Tam, Jane Yanagawa, Stephen C. Yang, Kristina M. Gregory, and Miranda Hughes

therapies, immunotherapies, and their respective biomarkers for eligible patients with NSCLC. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for NSCLC address all aspects of management for NSCLC. For the 2020 and 2021 updates, several

Full access

David S. Ettinger, Wallace Akerley, Hossein Borghaei, Andrew C. Chang, Richard T. Cheney, Lucian R. Chirieac, Thomas A. D'Amico, Todd L. Demmy, Ramaswamy Govindan, Frederic W. Grannis Jr, Stefan C. Grant, Leora Horn, Thierry M. Jahan, Ritsuko Komaki, Feng-Ming (Spring) Kong, Mark G. Kris, Lee M. Krug, Rudy P. Lackner, Inga T. Lennes, Billy W. Loo Jr, Renato Martins, Gregory A. Otterson, Jyoti D. Patel, Mary C. Pinder-Schenck, Katherine M. Pisters, Karen Reckamp, Gregory J. Riely, Eric Rohren, Theresa A. Shapiro, Scott J. Swanson, Kurt Tauer, Douglas E. Wood, Stephen C. Yang, Kristina Gregory, and Miranda Hughes

diesel fumes; see the NCCN Clinical Practice Guidelines in Oncology [NCCN Guidelines] for Lung Cancer Screening, available online at NCCN.org ). 1 , 4 , 12 , 13 NCCN Guidelines Insights : Non-Small Cell Lung Cancer, Version 2.2013 Version 2

Full access

Michael J. Berger, David S. Ettinger, Jonathan Aston, Sally Barbour, Jason Bergsbaken, Philip J. Bierman, Debra Brandt, Dawn E. Dolan, Georgiana Ellis, Eun Jeong Kim, Steve Kirkegaard, Dwight D. Kloth, Ruth Lagman, Dean Lim, Charles Loprinzi, Cynthia X. Ma, Victoria Maurer, Laura Boehnke Michaud, Lisle M. Nabell, Kim Noonan, Eric Roeland, Hope S. Rugo, Lee S. Schwartzberg, Bridget Scullion, John Timoney, Barbara Todaro, Susan G. Urba, Dorothy A. Shead, and Miranda Hughes

, 12 Although vomiting can often be prevented or substantially decreased by using prophylactic antiemetic regimens, nausea is much harder to control. 13 – 18 The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Antiemesis are

Full access

Kenneth C. Anderson, Melissa Alsina, Djordje Atanackovic, J. Sybil Biermann, Jason C. Chandler, Caitlin Costello, Benjamin Djulbegovic, Henry C. Fung, Cristina Gasparetto, Kelly Godby, Craig Hofmeister, Leona Holmberg, Sarah Holstein, Carol Ann Huff, Adetola Kassim, Amrita Y. Krishnan, Shaji K. Kumar, Michaela Liedtke, Matthew Lunning, Noopur Raje, Seema Singhal, Clayton Smith, George Somlo, Keith Stockerl-Goldstein, Steven P. Treon, Donna Weber, Joachim Yahalom, Dorothy A. Shead, and Rashmi Kumar

along with SPEP and SIFE yields high sensitivity while screening for MM and related plasma cell disorders. 7 Therefore, this assay is now included as a part of the initial diagnostic workup in the NCCN Clinical Practice Guidelines in Oncology (NCCN

Full access

NCCN Guidelines and NCCN Compendium Updated NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Colon Cancer. These NCCN Guidelines are currently available as Version 1.2011. A footnote was

Full access

John A. Thompson

suggested frontline and second-line therapies.” In the 2015 update to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Melanoma, the systemic therapy section was significantly revised by converting the “Preferred Regimens” and “Other

Full access

David G. Pfister, Kie-Kian Ang, David M. Brizel, Barbara A. Burtness, Paul M. Busse, Jimmy J. Caudell, Anthony J. Cmelak, A. Dimitrios Colevas, Frank Dunphy, David W. Eisele, Jill Gilbert, Maura L. Gillison, Robert I. Haddad, Bruce H. Haughey, Wesley L. Hicks Jr, Ying J. Hitchcock, Merrill S. Kies, William M. Lydiatt, Ellie Maghami, Renato Martins, Thomas McCaffrey, Bharat B. Mittal, Harlan A. Pinto, John A. Ridge, Sandeep Samant, David E. Schuller, Jatin P. Shah, Sharon Spencer, Randal S. Weber, Gregory T. Wolf, Frank Worden, Sue S. Yom, Nicole R. McMillian, and Miranda Hughes

A new section on “Principles of Nutrition” was recently added to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Head and Neck Cancers. This new section outlines the management of nutrition and supportive care for patients